未登录

E

Eugênio Cersósimo

university of texas system

H指数:43

被引数:7,232

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Mesenteric Visceral Lipectomy Improves Glucose Tolerance in Patients With Type 2 Diabetes: A Pilot Study

JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

IF5.1

2024-12-171

OA

Effect of dapagliflozin on renal haemodynamics in hyperfiltering T2D patients

DIABETES OBESITY & METABOLISM

IF5.7

2024-11-270

PRE

Effect of Hyperketonemia on Myocardial Function in Patients With Heart Failure and Type 2 Diabetes

IF7.5

2024-10-240

PRE

Effect of weight-maintaining ketogenic diet on glycemic control and insulin sensitivity in obese T2D subjects

BMJ OPEN DIABETES RESEARCH & CARE

IF4.1

2024-10-182

OAAI

Effect of Dapagliflozin on Renal and Hepatic Glucose Kinetics in T2D and NGT Subjects

IF7.5

2024-03-210

OA

Emergence of a New Glucoregulatory Mechanism for Glycemic Control With Dapagliflozin/Exenatide Therapy in Type 2 Diabetes

JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

IF5.1

2023-07-221

PRE

Pioglitazone reduces epicardial fat and improves diastolic function in patients with type 2 diabetes

DIABETES OBESITY & METABOLISM

IF5.7

2022-11-0415

OA

Dapagliflozin Impairs the Suppression of Endogenous Glucose Production in Type 2 Diabetes Following Oral Glucose

IF16.6

2022-03-027

OA

Combination therapy with pioglitazone/exenatide/metformin reduces the prevalence of hepatic fibrosis and steatosis: The efficacy and durability of initial combination therapy for type 2 diabetes (EDICT)

DIABETES OBESITY & METABOLISM

IF5.7

2022-02-0921

PRE

Effect of elevated plasma ketones on cardiac efficiency

AMERICAN HEART JOURNAL

IF3.5

2021-12-010

PREAI

Bromocriptine-QR (BQR) Ameliorates Immunocyte Pro-Oxidative Stress/Pro-inflammatory (POS/PI) and ER Stress Phenotype in T2DM Subjects

IF7.5

2021-06-010

PRE

Durability of Triple Combination Therapy Versus Stepwise Addition Therapy in Patients With New-Onset T2DM: 3-Year Follow-up of EDICT

IF16.6

2020-12-0335

OAAI

Improved Beta Cell Glucose Sensitivity Plays Predominant Role in the Decrease in HbA1c with Cana and Lira in T2DM

JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

IF5.1

2020-08-0311

OAAI

Clinical Parameters, Fuel Oxidation, and Glucose Kinetics in Patients With Type 2 Diabetes Treated With Dapagliflozin Plus Saxagliptin

IF16.6

2020-07-216

OAAI

Glucose Kinetics during Oral Glucose Challenge following Administration of Exenatide and Dapagliflozin Alone and in Combination in Type 2 Diabetes

IF7.5

2020-06-010

PRE

Combination Therapy with Dapagliflozin plus Exenatide on Endogenous Glucose Production: A Mechanism of Action Study

IF7.5

2020-06-010

PRE

Liver Fibrosis Scores Do Not Predict Response to Therapy in T2DM

IF7.5

2020-06-010

PRE

Bromocriptine-OR (BQR) Ameliorates a Pro-oxidative Stress/Proinflammatory (POS/PI) Monocyte Phenotype in Poorly Controlled T2DM Subjects

IF7.5

2020-06-010

PRE

Combination Therapy With Canagliflozin Plus Liraglutide Exerts Additive Effect on Weight Loss, but Not on HbA1c, in Patients With Type 2 Diabetes

IF16.6

2020-03-2731

OAAI

Increase in Endogenous Glucose Production With SGLT2 Inhibition Is Unchanged by Renal Denervation and Correlates Strongly With the Increase in Urinary Glucose Excretion

IF16.6

2020-03-0615

OAAI